Evidence map›Paper›PMID 19641203›Full record

Trial reportThe New England journal of medicine2009

Protection against a malaria challenge by sporozoite inoculation.

Meta Roestenberg, Matthew McCall, Joost Hopman, Jorien Wiersma, Adrian J F Luty, Geert Jan van Gemert, Marga van de Vegte-Bolmer, Ben van Schaijk, Karina Teelen, Theo Arens and 8 more

11 registry-linked trialsOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The New England journal of medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 11 registered trials, which are not on this map. Cited by 334 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
334citing papers in PubMed, 1 pooled it
46.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00442377 nacompletednot on this map

Exposure of Human Volunteers to Live Malaria Sporozoites Under Chloroquine Prophylaxis

TypeinterventionalSponsorRadboud University Medical CenterRan2007 to 2007Enrolled15ConditionsFalciparum MalariaArmsexposure to malaria sporozoites
NCT01236612 nacompletednot on this mapstarted 2011, after this paper: background citation

Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis

TypeinterventionalSponsorRadboud University Medical CenterRan2011 to 2012Enrolled25ConditionsPlasmodium Falciparum MalariaArmsChloroquine prophylaxis, Immunization, Plasmodium falciparum Bloodstage challenge, Plasmodium falciparum mosquito challenge, Malarone treatment
NCT01660854 nacompletednot on this mapstarted 2012, after this paper: background citation

Re-exposure of Previously Immunized and Challenged Human Volunteers to a Heterologous Strain of P. Falciparum Sporozoites

TypeinterventionalSponsorRadboud University Medical CenterRan2012 to 2013Enrolled21ConditionsMalaria, FalciparumArmsHeterologous challenge, Malarone treatment
NCT01783340 phase1 / phase2withdrawnnot on this mapstarted 2013, after this paper: background citation

Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis

TypeinterventionalSponsorRadboud University Medical CenterRan2013 to 2014Enrolled0ConditionsMalaria, FalciparumArmsAzithromycin capsules, Placebo, Immunization with falciparum
NCT02080026 nacompletednot on this mapstarted 2014, after this paper: background citation

Identification of Pre-erythrocytic Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis

TypeinterventionalSponsorRadboud University Medical CenterRan2014 to 2015Enrolled15ConditionsMalariaArmsCPS-immunization, Controlled Human Malaria Infection, chloroquine, atovaquone/proguanil
NCT02098590 nacompletednot on this mapstarted 2014, after this paper: background citation

Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection

TypeinterventionalSponsorRadboud University Medical CenterRan2014 to 2015Enrolled40ConditionsMalariaArmsCPS-immunization, malaria challenge infection, P. falciparum NF135.C10, malaria challenge infection, P. falciparum NF166.C8, malaria challenge infection, P. falciparum NF54, atovaquone/proguanil
NCT02511054 phase1completednot on this mapstarted 2015, after this paper: background citation

Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual Blood Stages of Plasmodium Falciparumc

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2015 to 2017Enrolled57ConditionsMalariaArmsChloroquine (CQ), Pyrimethamine (PYR), Sanaria PfSPZ Challenge (NF54)
NCT02925403 phase1 / phase2completednot on this mapstarted 2016, after this paper: background citation

A Phase Ib Randomised, Controlled, Single-blind Study to Assess the Safety, Immunogenicity of the Malaria Vaccine Candidate R21 With Matrix-M1 Adjuvant in West African Adult Volunteers

TypeinterventionalSponsorUniversity of OxfordRan2016 to 2017Enrolled13ConditionsMalariaArmsR21/Matrix-M1, Saline
NCT03083847 phase1completednot on this mapstarted 2017, after this paper: background citation

Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Dose Escalation Trial to Determine Safety and Development of Protective Efficacy After Exposure to Only Pre-erythrocytic Stages of Plasmodium Falciparum

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2017 to 2019Enrolled55ConditionsMalariaArmsChloroquine Phosphate, Pyrimethamine, Sanaria PfSPZ Challenge
NCT03952650 phase1 / phase2completednot on this mapstarted 2019, after this paper: background citation

Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falciparum Infection in Bancoumana and Surrounding Areas, Mali

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2019 to 2021Enrolled252ConditionsMalariaArmsChloroquine Phosphate, PfSPZ Challenge, Pyrimethamine, Coartem, ibuprofen
NCT04577066 phase1 / phase2completednot on this mapstarted 2021, after this paper: background citation

Safety and Protective Efficacy of Genetically Attenuated Pf∆mei2 (Also Referred to as GA2) Malaria Parasites in Healthy Dutch Volunteers.

TypeinterventionalSponsorLeiden University Medical CenterRan2021 to 2022Enrolled43ConditionsPlasmodium Falciparum MalariaArmsGA2, GA1, Placebo
3 · Its place in the literature

Who cites it

334 citing papers in PubMed, 1 synthesis or guideline pooled it, 578 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Protection againstJCI insight · 2017
    Trial
  20. Trial

274 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 3 countries.

Meta RoestenbergDepartment of Medical Microbiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Matthew McCall
Joost Hopman
Jorien Wiersma
Adrian J F Luty
Geert Jan van Gemert
Marga van de Vegte-Bolmer
Ben van Schaijk
Karina Teelen
Theo Arens
Lopke Spaarman
Quirijn de Mast
Will Roeffen
Georges Snounou
Laurent Rénia
Andre van der Ven
Cornelus C Hermsen
Robert Sauerwein
Radboud University Nijmegen · NLSingapore Immunology Network · SGSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn effective vaccine for malaria is urgently needed. Naturally acquired immunity to malaria develops slowly, and induction of protection in humans can be achieved artificially by the inoculation of radiation-attenuated sporozoites by means of more than 1000 infective mosquito bites.

methodsWe exposed 15 healthy volunteers--with 10 assigned to a vaccine group and 5 assigned to a control group--to bites of mosquitoes once a month for 3 months while they were receiving a prophylactic regimen of chloroquine. The vaccine group was exposed to mosquitoes that were infected with Plasmodium falciparum, and the control group was exposed to mosquitoes that were not infected with the malaria parasite. One month after the discontinuation of chloroquine, protection was assessed by homologous challenge with five mosquitoes infected with P. falciparum. We assessed humoral and cellular responses before vaccination and before the challenge to investigate correlates of protection.

resultsAll 10 subjects in the vaccine group were protected against a malaria challenge with the infected mosquitoes. In contrast, patent parasitemia (i.e., parasites found in the blood on microscopical examination) developed in all five control subjects. Adverse events were mainly reported by vaccinees after the first immunization and by control subjects after the challenge; no serious adverse events occurred. In this model, we identified the induction of parasite-specific pluripotent effector memory T cells producing interferon-gamma, tumor necrosis factor alpha, and interleukin-2 as a promising immunologic marker of protection.

conclusionsProtection against a homologous malaria challenge can be induced by the inoculation of intact sporozoites. (ClinicalTrials.gov number, NCT00442377.)

Indexed as

Malaria VaccinesPlasmodium falciparumAdultAnimalsAnophelesAntibodies, ProtozoanAntimalarialsBiomarkersBloodChloroquineDouble-Blind MethodHumansInterferon-gammaInterleukin-2Malaria, FalciparumParasitemiaAntibodies, ProtozoanAntimalarialsBiomarkersChloroquineInterferon-gammaInterleukin-2Malaria VaccinesTumor Necrosis Factor-alpha

Identifiers

PMID19641203
OpenAlexW2169790609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 5 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.